Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding

To observe and access the Effects and safety of terlipressin or high dose somatostatin/octreotide when usual dose somatostatin/octreotide fail to achieve hemostasis in patients with acute variceal bleeding.

The prognosis information of the patients with acute variceal bleeding will be collected, including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse events, economic burdens and quality of life, when terlipressin or high dose somatostatin/octreotide is used as salvation to patients fail to achieve initial hemostasis.The results may help gastroenterologists to make decisions when administering vasoactive medicines to those suffered from acute variceal bleeding.

Inclusion Criteria:

• Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding

Exclusion Criteria:

• No signs of variceal bleeding are found by endoscopy or portal hypertensive gastropathy is responsible for the bleeding
• Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding
• Patients with hepatorenal syndrome
• Patients with ischemia organic cardiopathy (including myocardial infarction or unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months
• Patients allergic to/with contraindications of vasoactive drugs